No Data
No Data
No Data
No Data
No Data
Is Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Recent Stock Performance Tethered To Its Strong Fundamentals?
Zhejiang Huahai Pharmaceutical (SHSE:600521) has had a great run on the share market with its stock up by a significant 47% over the last three months. Since the market usually pay for a company's l
Simply Wall StMay 5 21:09 ET
Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21%
Zhejiang Huahai Pharmaceutical (SHA:600521) booked a net profit attributable to shareholders of 270.8 million yuan in the first quarter of the year, jumping 56.6% from 172.9 million yuan a year earlie
MT NewswiresMay 2 03:50 ET
Huahai Pharmaceutical (600521.SH): Controlling shareholder and actual controller Chen Baohua increased his total holdings of the company by 3.18 million shares
Gelonghui, April 30 | Huahai Pharmaceutical (600521.SH) announced that as of the disclosure date of this announcement, Mr. Chen Baohua, the controlling shareholder and actual controller of the company, had increased his holdings of the Company's shares by 3.18 million shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 0.21% of the company's total share capital. The total amount of increase in holdings was 49,518,278 yuan. The actual amount of Mr. Chen Baohua's holdings increase this time has exceeded the lower limit of the range of the holdings increase plan, and the implementation period for the increase in holdings has expired, and the implementation of the current holdings increase plan has been completed.
Gelonghui FinanceApr 30 05:43 ET
Huahai Pharmaceutical Gets Approval to Market Busulfan Injection
Zhejiang Huahai Pharmaceutical (SHA:600521) received a drug registration certificate from China's National Medical Products Administration for its busulfan injection, according to the company's disclo
MT NewswiresApr 23 23:47 ET
Huahai Pharmaceutical (600521.SH): Busulan injection obtained a drug registration certificate
Gelonghui, April 23 | Huahai Pharmaceutical (600521.SH) announced that the company recently received the “Drug Registration Certificate” for the Bexuan injection approved and issued by the State Drug Administration. Busulinan injection is suitable for use with cyclophosphamide as a pretreatment plan for hematopoietic progenitor cells of chronic myeloid leukemia before transplantation.
Gelonghui FinanceApr 23 05:58 ET
Huahai Pharmaceutical (600521.SH) completed the repurchase of 7.023,600 shares at a cost of about 100 million yuan
Huahai Pharmaceutical (600521.SH) announced that on April 17, 2024, the company completed the repurchase and actually repurchased the public...
Zhitong FinanceApr 18 06:40 ET
No Data
No Data